Focus: Corbus Pharmaceuticals is a specialty biotech focused on orphan inflammatory-fibrotic diseases with a pipeline spanning immunology, neurology, and rare diseases. Headquartered in Norwood, MA, the company operates at mid-cap biotech scale with a lean active job count of 5 roles.
Profile data last refreshed 9m ago · AI intelligence enriched 1mo ago
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
A specialized rare-disease biotech with a solid clinical pipeline and recent leadership upgrade, suitable for specialists seeking deep immunology/fibrotic disease expertise but risky for those prioritizing job security or rapid advancement in a growing organization.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Corbus Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corbus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial Stock Titan
8-K Filing: Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) — EX-99.1
EX-99.1
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? StockInvest.us
BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals - Stock Titan
BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast CNN
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer citybiz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.
Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo